These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24561431)

  • 61. Gene expression profiling of leukemia stem cells.
    Krivtsov AV; Wang Y; Feng Z; Armstrong SA
    Methods Mol Biol; 2009; 538():231-46. PubMed ID: 19277590
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 63. Stem cells: bad seeds.
    Willyard C
    Nature; 2013 Jun; 498(7455):S12-3. PubMed ID: 23803943
    [No Abstract]   [Full Text] [Related]  

  • 64. Mutant molecules of interest in myeloproliferative neoplasms: introduction.
    Tefferi A
    Acta Haematol; 2008; 119(4):192-3. PubMed ID: 18566535
    [No Abstract]   [Full Text] [Related]  

  • 65. Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
    Cagnetta A; Soncini D; Orecchioni S; Talarico G; Minetto P; Guolo F; Retali V; Colombo N; Carminati E; Clavio M; Miglino M; Bergamaschi M; Nahimana A; Duchosal M; Todoerti K; Neri A; Passalacqua M; Bruzzone S; Nencioni A; Bertolini F; Gobbi M; Lemoli RM; Cea M
    Haematologica; 2018 Jan; 103(1):80-90. PubMed ID: 29025907
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The increasing genomic complexity of acute myeloid leukemia.
    Rowe JM
    Best Pract Res Clin Haematol; 2014; 27(3-4):209-13. PubMed ID: 25455268
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.
    Wouters R; Cucchi D; Kaspers GJ; Schuurhuis GJ; Cloos J
    Expert Rev Hematol; 2014 Dec; 7(6):791-805. PubMed ID: 25242511
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
    Wouters BJ; Delwel R
    Blood; 2016 Jan; 127(1):42-52. PubMed ID: 26660432
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3B.
    Itonaga H; Imanishi D; Wong YF; Sato S; Ando K; Sawayama Y; Sasaki D; Tsuruda K; Hasegawa H; Imaizumi Y; Taguchi J; Tsushima H; Yoshida S; Fukushima T; Hata T; Moriuchi Y; Yanagihara K; Miyazaki Y
    Leukemia; 2014 Jul; 28(7):1459-66. PubMed ID: 24457336
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches.
    Mesuraca M; Amodio N; Chiarella E; Scicchitano S; Aloisio A; Codispoti B; Lucchino V; Montalcini Y; Bond HM; Morrone G
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30126100
    [TBL] [Abstract][Full Text] [Related]  

  • 71. RIPK3-dependent cell death and inflammasome activation in FLT3-ITD expressing LICs.
    Höckendorf U; Yabal M; Jost PJ
    Oncotarget; 2016 Sep; 7(36):57483-57484. PubMed ID: 27517160
    [No Abstract]   [Full Text] [Related]  

  • 72. High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia.
    Grossmann V; Schnittger S; Poetzinger F; Kohlmann A; Stiel A; Eder C; Fasan A; Kern W; Haferlach T; Haferlach C
    Leukemia; 2013 Sep; 27(9):1933-6. PubMed ID: 23535558
    [No Abstract]   [Full Text] [Related]  

  • 73. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
    Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
    Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Development and validation of GMI signature based random survival forest prognosis model to predict clinical outcome in acute myeloid leukemia.
    Shi M; Xu G
    BMC Med Genomics; 2019 Jun; 12(1):90. PubMed ID: 31242922
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Leukemia stem cell].
    Iwasaki H
    Gan To Kagaku Ryoho; 2014 Mar; 41(3):280-4. PubMed ID: 24743272
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Characterizing the In Vivo Role of Candidate Leukemia Stem Cell Genes.
    Zhang YW; Mess J; Cabezas-Wallscheid N
    Methods Mol Biol; 2021; 2185():307-316. PubMed ID: 33165857
    [TBL] [Abstract][Full Text] [Related]  

  • 78. MicroRNAs: new players in acute myeloid leukaemia.
    Havelange V; Garzon R; Croce CM
    Br J Cancer; 2009 Sep; 101(5):743-8. PubMed ID: 19672257
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia.
    Xu Z; Wang M; Wang L; Wang Y; Zhao X; Rao Q; Wang J
    Leuk Res; 2009 Jul; 33(7):891-7. PubMed ID: 19250671
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
    Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
    Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.